RBC Transfusions for Sickle Cell Disease: Benefits and Risks in Children

Understanding Sickle Cell Disease and Transfusion Methods

Sickle cell disease is an inherited blood disorder where oxygen-carrying red blood cells become rigid, crescent-shaped, and sticky rather than flexible and disc-shaped. These abnormal cells break apart easily, causing anemia, and can block blood vessels to trigger severe pain, tissue damage, and organ injury. Medical providers utilize healthy red blood cell transfusions in several distinct ways to manage these complications. Patients may receive a simple top-up transfusion of normal blood to correct anemia, or an exchange transfusion where sickle-cell blood is removed and replaced with normal blood to reduce the proportion of sickled RBCs during emergencies like strokes or acute chest syndrome. Long-term, regular monthly transfusions are also deployed to prevent strokes, particularly when medications such as hydroxycarbamide prove ineffective.

Evidence on Stroke Prevention and Clinical Complications

The updated Cochrane overview analyzed 17 relevant reviews and identified nine studies involving 1,502 participants that provided usable data on transfusion effects. For children and adolescents identified as high-risk via specialized ultrasound testing, or those who have suffered a silent stroke without outward symptoms, long-term red blood cell transfusions compared to standard care probably decrease the risk of stroke. The data shows these regular transfusions may decrease the risk of painful crises, acute chest syndrome, and silent strokes in children with abnormal ultrasound results. Across the analyzed studies, death from any cause was very rare, showing little or no difference in mortality risk regardless of the treatment approach.

Transfusion Risks and Extended Matching Standards

While therapeutic, red blood cell transfusions carry documented adverse effects, including a heightened risk of iron overload and the development of antibodies against transfused red blood cells, a process known as alloimmunization. According to the Canadian Medical Association Journal, two-thirds of patients receiving regular transfusions show evidence of red blood cell alloimmunization. To mitigate these risks, extended red blood cell antigen profiling should be performed before a patient’s first transfusion, matching donor blood for Rh and Kell antigens. Maintaining a comprehensive transfusion history helps blood banks select appropriate components and prevents delayed hemolytic reactions upon re-exposure.

Population Limitations and Research Gaps

The current evidence base presents notable limitations regarding patient demographics and geographic scope. All nine studies evaluated in the review were conducted in high-income nations including the United States, Canada, France, and the United Kingdom, meaning findings may not apply directly to low- and middle-income countries where transfusion access and associated risks differ. Most of the existing data focuses on children with HbSS disease, leaving significant gaps regarding adults with sickle cell disease complications and pediatric patients with other variants of the condition. Important metrics such as quality of life were also frequently omitted from reported study outcomes.